Form 8-K Sage Therapeutics, Inc. For: Jan 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC
January 7, 2019 1:03 PM ESTRBC Capital analyst Brian Abrahams weighed in on Sage Therapeutics (NASDAQ: SAGE) following a Q&A session hosted by management, which the analyst noted offered mostly incremental tidbits, and overall supports their comfort and enthusiasm around efficacy/safety of 217 in PPD and... More
SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen
January 7, 2019 11:56 AM ESTCowen analyst Ritu Baral reiterated an Outperform rating and $207 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported highly positive top-line data from the Ph3 ROBIN study of SAGE-217 in postpartum depression.
Baral commented, "The trial met primary endpoint with... More
Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO
January 7, 2019 11:52 AM ESTBMO Capital analyst Gary Nachman reiterated an Outperform rating and $203 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported "very impressive" Ph3 data for SAGE-217 in PPD that demonstrated strong efficacy across the board and an overall good safety... More
Sage Therapeutics (SAGE) PT Raised to $90 at Leerink Partners
January 7, 2019 11:48 AM ESTLeerink Partners analyst Marc Goodman raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $80.00) while maintaining a Underperform rating.
... More